 Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that new translational research for second-generation Bicycle Toxin Conjugate BTC BT5528 and preclinical data for novel, fully synthetic tumor-targeted immune cell agonists TICAsTM BT7480 and BT7455 will be presented during poster sessions at the American Association for Cancer Research AACR Virtual Annual Meeting II on June 22-24, 2020. All e-posters will be made available for browsing on AACRs e-poster website starting June 22. 